Allorion Therapeutics announced that it has received $50 million in a round of funding led by new investor INCE Management Consulting (Shanghai) Co., Ltd., and returning investor Qiming Weichuang Venture Capital Management (Shanghai) Company Limited on March 9, 2023. The transaction included participation from 3SBio, and new investor Long River Investments and returning investors TF Capital, Octagon Capital Advisors LP, Elikon Venture. The company has received $100 million funding till date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.08 HKD | +0.50% | +9.35% | -19.15% |
Apr. 22 | 3Sbio Inc. Announces Management Changes | CI |
Apr. 15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.15% | 1.85B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- 1530 Stock
- News 3SBio Inc.
- Allorion Therapeutics announced that it has received $50 million in funding from a group of investors